生产企业：Akari Therapeutics Plc
AKTX-101 is an investigational TROP2-targeting ADC with a PH1 RNA spliceosome-modulating payload, developed by Akari Therapeutics for KRAS-mutated pancreatic cancer. IND-enabling studies are underway with a Phase 1 trial expected by mid-2027.
AKTX-101 is an investigational TROP2-targeting ADC with a PH1 RNA spliceosome-modulating payload, developed by Akari Therapeutics for KRAS-mutated pancreatic cancer. IND-enabling studies are underway with a Phase 1 trial expected by mid-2027.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
